Genomtec S.A.
Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company's flagship project is the Genomtec ID, a diagnostic platform that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analysi… Read more
Genomtec S.A. (GMT) - Total Liabilities
Latest total liabilities as of September 2025: zł5.84 Million PLN
Based on the latest financial reports, Genomtec S.A. (GMT) has total liabilities worth zł5.84 Million PLN as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Genomtec S.A. - Total Liabilities Trend (2019–2024)
This chart illustrates how Genomtec S.A.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Genomtec S.A. Competitors by Total Liabilities
The table below lists competitors of Genomtec S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Trio-Tech International
NYSE MKT:TRT
|
USA | $13.99 Million |
|
GeeCee Ventures Limited
NSE:GEECEE
|
India | ₹5.43 Billion |
|
Cerberus Cyber Sentinel Corp
NASDAQ:CISO
|
USA | $8.74 Million |
|
Avrasya Petrol ve Turistik Tesisler Yatirimlar AS
IS:AVTUR
|
Turkey | TL197.96 Million |
|
Black Rock Mining Ltd
AU:BKT
|
Australia | AU$3.09 Million |
|
Idex ASA
OL:IDEX
|
Norway | Nkr5.55 Million |
|
Cybertech Systems And Software Limited
NSE:CYBERTECH
|
India | ₹1.35 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Genomtec S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genomtec S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genomtec S.A. (2019–2024)
The table below shows the annual total liabilities of Genomtec S.A. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | zł9.44 Million | +23.09% |
| 2023-12-31 | zł7.67 Million | +11.68% |
| 2022-12-31 | zł6.87 Million | +97.47% |
| 2021-12-31 | zł3.48 Million | +93.33% |
| 2020-12-31 | zł1.80 Million | -0.13% |
| 2019-12-31 | zł1.80 Million | -- |